Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s117200 ◽

2016 ◽

Vol Volume 9 ◽

pp. 19-29 ◽

Cited By ~ 11

Author(s):

Jay Lin ◽

Melissa Lingohr-Smith ◽

Tao Fan

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Real World ◽

Receptor Agonist ◽

Medication Persistence ◽

The Us ◽

Dose Combination ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study

Diabetes & Metabolism Journal ◽

10.4093/dmj.2021.0232 ◽

2021 ◽

Author(s):

Hwi Seung Kim ◽

Taekwan Yoon ◽

Chang Hee Jung ◽

Joong-Yeol Park ◽

Woo Je Lee

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Combination Therapy ◽

Real World ◽

Receptor Agonist ◽

Sodium Glucose Cotransporter ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

Clinical Diabetes ◽

10.2337/cd17-0065 ◽

2018 ◽

Vol 36 (2) ◽

pp. 138-147 ◽

Cited By ~ 4

Author(s):

Vanita R. Aroda ◽

Joseph R. Arulandu ◽

Anthony J. Cannon

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Receptor Agonist ◽

Two Agents ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Better Than

Download Full-text

Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence

Obesity Science & Practice ◽

10.1002/osp4.116 ◽

2017 ◽

Vol 3 (3) ◽

pp. 342-351 ◽

Cited By ~ 12

Author(s):

G. S. Carls ◽

R. Tan ◽

J. Y. Zhu ◽

E. Tuttle ◽

J. Yee ◽

...

Keyword(s):

Type 2 Diabetes ◽

Medication Adherence ◽

Real World ◽

Weight Change ◽

Receptor Agonist ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Type 2 diabetes in the US managed care setting: the burden of disease and rationale for an oral glucagon-like peptide-1 receptor agonist

The American Journal of Managed Care ◽

10.37765/ajmc.2020.88552 ◽

2020 ◽

Vol 26 (Suppl 16) ◽

pp. S325-S334

Keyword(s):

Type 2 Diabetes ◽

Managed Care ◽

Burden Of Disease ◽

Receptor Agonist ◽

Care Setting ◽

The Us ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Real-World Comparative Effectiveness, Treatment Patterns, and Costs in Type 2 Diabetes Mellitus (T2DM) Patients Initiated on Canagliflozin 300 mg (CANA) or a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1)

Diabetes ◽

10.2337/db18-1287-p ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 1287-P

Author(s):

MUKUL SINGHAL ◽

HIANGKIAT (JASON) TAN ◽

CRAIG I. COLEMAN ◽

WILLIAM H. HERMAN ◽

JENNIFER CAI ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Real World ◽

Comparative Effectiveness ◽

Receptor Agonist ◽

Treatment Patterns ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Practical Considerations and Rationale for Glucagon-like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2020.09.005 ◽

2020 ◽

Author(s):

Ronald M. Goldenberg ◽

Vineeta Ahooja ◽

Kristin K. Clemens ◽

Jeremy D. Gilbert ◽

Megha Poddar ◽

...

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Receptor Agonist ◽

Sodium Dependent ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Inhibitor Combination

Download Full-text

Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Diabetes Care ◽

10.2337/dc16-1957 ◽

2017 ◽

Vol 40 (4) ◽

pp. 614-624 ◽

Cited By ~ 52

Author(s):

Maria Ida Maiorino ◽

Paolo Chiodini ◽

Giuseppe Bellastella ◽

Annalisa Capuano ◽

Katherine Esposito ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Combination Therapy ◽

Receptor Agonist ◽

Meta Analysis ◽

Controlled Trials ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2021.109035 ◽

2021 ◽

Vol 180 ◽

pp. 109035

Author(s):

Federico Rea ◽

Stefano Ciardullo ◽

Laura Savaré ◽

Gianluca Perseghin ◽

Giovanni Corrao

Keyword(s):

Type 2 Diabetes ◽

Real World ◽

Medication Persistence ◽

Receptor Agonists ◽

Real World Setting ◽

Sodium Glucose Cotransporter ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations

Postgraduate Medicine ◽

10.1080/00325481.2018.1450058 ◽

2018 ◽

Vol 130 (4) ◽

pp. 375-380 ◽

Cited By ~ 4

Author(s):

Ian Blumer ◽

Jeremy H. Pettus ◽

Tricia Santos Cavaiola

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Receptor Agonist ◽

Fixed Ratio ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2018.09.001 ◽

2019 ◽

Vol 43 (3) ◽

pp. 186-192 ◽

Cited By ~ 6

Author(s):

Juana Carretero Gómez ◽

José Carlos Arévalo Lorido ◽

Ricardo Gómez Huelgas ◽

Dolores García de Lucas ◽

Lourdes Mateos Polo ◽

...

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Real World ◽

Older Patients ◽

Receptor Agonists ◽

Sodium Glucose Cotransporter ◽

Real World Evidence ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text